Chronic Pain Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Novel Non-Opioid Pain Therapies and Innovative Chronic Pain Drugs | DelveInsight

The Chronic Pain Market is growing due to the rising prevalence of chronic pain conditions, an aging population, increasing musculoskeletal and neuropathic disorders, and demand for non-opioid therapies. Advances in pain management and emerging treatments such as ZILOSUL, HP-5000, AMZ001, TNX-102 SL, CGS-200-5, and Resiniferatoxin are expected to drive market growth during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Chronic Pain Market Insights, Epidemiology, and Market Forecast - 2036." This comprehensive report provides an in-depth understanding of Chronic Pain Epidemiology, Chronic Pain Market Size, Chronic Pain Pipeline, Chronic Pain Clinical Trials, market trends, treatment landscape, and emerging Chronic Pain Therapies across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan (7MM).

Key Takeaways from the Chronic Pain Market

*
The Chronic Pain Market Size across the 7MM is expected to grow significantly by 2036, driven by increasing disease prevalence, improved diagnosis, expanding treatment accessibility, and the anticipated launch of several innovative Chronic Pain Drugs.

*
The United States accounted for the largest Chronic Pain Treatment Market size among the 7MM in 2025 and is expected to maintain its dominance throughout the forecast period owing to high diagnosis rates, favorable reimbursement, and increasing adoption of novel pain therapeutics.

*
According to DelveInsight's analysis, the Chronic Pain Market in the 7MM is projected to increase from approximately USD 9.9 billion in 2022 to nearly USD 22.9 billion by 2036, representing significant opportunities for pharmaceutical companies developing innovative pain management drugs and non-opioid pain therapies.

*
According to the US Pain Foundation (2023), chronic pain affects nearly 21% of adults in the United States, representing approximately 51.6 million people, while nearly 17.1 million individuals suffer from high-impact chronic pain that substantially limits daily activities and quality of life.

*
According to Katzman et al. (2024), nearly 50 million Americans currently live with chronic pain, emphasizing the substantial unmet medical need and the growing demand for effective Chronic Pain Therapeutics.

*
According to Jacqueline et al. (2024), chronic pain prevalence increases considerably with age, affecting 12.3% of adults aged 18-29 years and increasing to 36.0% among adults aged 65 years and older. Women experience chronic pain more frequently than men, accounting for 25.4% versus 23.2%, respectively.

*
According to Lucas et al. (2024), American Indian and Alaska Native adults demonstrate the highest prevalence of chronic pain (30.7%) compared with other racial and ethnic populations, while chronic pain is also more common in rural communities than urban settings.

*
According to Alexander et al. (2024), approximately 5-14% of patients with chronic pain report lifetime suicide attempts, while nearly 20% experience suicidal ideation, highlighting the substantial psychosocial burden associated with chronic pain disorders.

*
Within the 7MM, approximately 70% of diagnosed patients experience moderate-to-severe chronic pain, whereas chronic back pain remains the leading cause-specific condition, accounting for nearly 55% of diagnosed chronic pain cases.

*
Leading Chronic Pain Companies, including Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Amzell, Tonix Pharmaceuticals, Propella Therapeutics, Grunenthal, and others, are actively advancing innovative Chronic Pain Pipeline assets that are expected to reshape the future Pain Management Market.

*
The promising Chronic Pain Drugs in clinical development include ZILOSUL, HP-5000, AMZ001, TNX-102 SL, CGS-200-5, Resiniferatoxin, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Chronic Pain Market

Increasing Prevalence of Chronic Pain Disorders: Rising cases of chronic low back pain, osteoarthritis pain, rheumatoid arthritis, neuropathic pain, fibromyalgia, migraine, cancer pain, and post-operative pain continue to drive demand for innovative pain therapeutics across the global Chronic Pain Market.

Growing Demand for Non-Opioid Pain Therapies: Increasing concerns regarding opioid dependence, addiction, overdose risk, and long-term safety have accelerated the development of safer non-opioid chronic pain treatments, creating substantial opportunities for next-generation analgesics.

Advances in Precision Pain Management and Multimodal Therapies: The integration of pharmacological therapies, interventional pain management, neuromodulation, rehabilitation, behavioral therapies, and personalized medicine is transforming the treatment paradigm for chronic pain and improving long-term patient outcomes.

Strong Chronic Pain Drug Pipeline: Multiple biotechnology and pharmaceutical companies are advancing innovative Chronic Pain Clinical Trials involving novel mechanisms targeting inflammation, tissue regeneration, CGRP signaling, TRPV1 pathways, peripheral nerve sensitization, and neuroimmune modulation, which are expected to significantly expand future treatment options.

Chronic Pain Competitive Landscape

The Chronic Pain Pipeline remains highly active, with several innovative therapies progressing through late-stage clinical development. Key pipeline candidates include ZILOSUL (Paradigm Biopharmaceuticals), HP-5000 (Noven Pharmaceuticals), AMZ001 (Amzell), TNX-102 SL (Tonix Pharmaceuticals), CGS-200-5 (Propella Therapeutics), and Resiniferatoxin (Grunenthal).

These investigational therapies utilize diverse mechanisms, including tissue regeneration, anti-inflammatory activity, transdermal drug delivery systems, topical NSAID formulations, TRPV1 receptor agonism, and non-opioid analgesic approaches designed to provide sustained pain relief while minimizing opioid-related adverse events. Their differentiated mechanisms position them among the most promising emerging chronic pain therapies expected to transform the Pain Management Market over the coming decade.

Discover more about therapies set to grab major Chronic Pain Market share @ Chronic Pain Treatment Landscape [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Chronic Pain Market

*
In April 2025, Tonix Pharmaceuticals presented positive data at the American Academy of Pain Medicine (AAPM) Annual Meeting, demonstrating that TNX-102 SL achieved statistically significant improvements in fibromyalgia pain reduction across two pivotal Phase III clinical studies, successfully meeting their primary endpoints.

*
Paradigm Biopharmaceuticals continues to advance ZILOSUL (pentosan polysulfate sodium) through Phase III clinical development for knee osteoarthritis-associated pain following US FDA Fast Track designation.

*
Noven Pharmaceuticals has successfully completed Phase III clinical development of HP-5000, a transdermal diclofenac sodium formulation designed for osteoarthritis knee pain management.

*
Amzell continues to advance AMZ001, a high-strength topical diclofenac sodium formulation intended for osteoarthritis pain and other chronic pain conditions, while expanding its broader pain management pipeline.

What is Chronic Pain?

Chronic Pain is a complex, long-lasting medical condition characterized by persistent or recurrent pain lasting three months or longer, often continuing beyond the normal period of tissue healing. Chronic pain encompasses a broad spectrum of disorders, including chronic low back pain, neuropathic pain, osteoarthritis pain, rheumatoid arthritis, fibromyalgia, migraine, cancer pain, neuralgia, and post-operative pain. The condition significantly affects physical function, emotional well-being, productivity, and quality of life while imposing a substantial socioeconomic burden worldwide. Current Chronic Pain Treatment strategies involve a multidisciplinary approach incorporating pharmacological therapies, non-opioid analgesics, opioids, antidepressants, anticonvulsants, interventional pain procedures, physical rehabilitation, behavioral therapy, and complementary medicine. Continued innovation in Chronic Pain Drug Development, personalized medicine, and non-opioid pain management approaches is expected to reshape the future treatment landscape and improve long-term patient outcomes.

Chronic Pain Epidemiology Segmentation

The Chronic Pain epidemiology section provides insights into the historical and current Chronic Pain patient pool and forecasted trends for the leading markets. The Chronic Pain market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:

*
Total Diagnosed Prevalent Cases of Chronic Pain

*
Gender-specific Diagnosed Prevalent Cases of Chronic Pain

*
Age-specific Diagnosed Prevalent Cases of Chronic Pain

*
Severity-specific Diagnosed Prevalent Cases of Chronic Pain

*
Cause-specific Diagnosed Prevalent Cases of Chronic Pain

Scope of the Chronic Pain Market Report

*
Therapeutic Assessment: Current marketed and emerging Chronic Pain Therapies

*
Chronic Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Pain Drugs, Market Drivers, Market Barriers, and Future Market Outlook

*
Key Companies: Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Amzell, Tonix Pharmaceuticals, Propella Therapeutics, Grunenthal, Vertex Pharmaceuticals, Tris Pharma, Centrexion Therapeutics, Algiax Pharmaceuticals, and others

*
Key Therapies: ZILOSUL (pentosan polysulfate sodium), HP-5000, AMZ001, TNX-102 SL, CGS-200-5, Resiniferatoxin, VX-548 (Suzetrigine), Cebranopadol, AP-325, and others

*
Competitive Intelligence Analysis: SWOT Analysis, PESTLE Analysis, Porter's Five Forces, BCG Matrix, and Market Entry Strategies

*
Unmet Needs, KOL's Views, Analyst's Views, Chronic Pain Market Access and Reimbursement

To know more about Chronic Pain companies working in the treatment market, visit @ Chronic Pain Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Chronic Pain Market Report Introduction

*
Executive Summary for Chronic Pain

*
SWOT Analysis of Chronic Pain

*
Chronic Pain Patient Share (%) Overview at a Glance

*
Chronic Pain Market Overview at a Glance

*
Chronic Pain Background and Overview

*
Chronic Pain Epidemiology and Patient Population

*
Country-Specific Patient Population of Chronic Pain

*
Chronic Pain Current Treatment and Medical Practices

*
Chronic Pain Unmet Needs

*
Chronic Pain Emerging Therapies

*
Chronic Pain Market Outlook

*
Country-Wise Chronic Pain Market Analysis (2022-2036)

*
Chronic Pain Market Access and Reimbursement of Therapies

*
Chronic Pain Market Drivers

*
Chronic Pain Market Barriers

*
Chronic Pain Appendix

*
Chronic Pain Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pain-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-novel-nonopioid-pain-therapies-and-innovative-chronic-pain-drugs-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.